Q4 2025 · 13F-HR
Finepoint Capital LPholdings as filed
Filed 2026-02-13 · accession 0000904454-26-000098
$2.00B
Reported value
9
Positions
2025-12-31
Period end
The Brief · Finepoint Capital LP · Q4 2025
AI · grounded in 13F
Finepoint Capital LP increased its position in SPY by 30.29%. The fund also accumulated shares of RXO by 29.20%. Conversely, the manager trimmed its holding in QXO by 5.02%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78462F103 | SPY | SPDR S&P 500 ETF TR | $1.07B | 53.5% | 1,573,200 | PUT | SOLE |
| 82846H405 | QXO | QXO INC | $408.5M | 20.4% | 21,177,415 | Common | SOLE |
| 464287655 | IWM | ISHARES TR | $398.0M | 19.9% | 1,617,000 | PUT | SOLE |
| 74982T103 | RXO | RXO INC | $118.7M | 5.92% | 9,388,789 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $5.4M | 0.27% | 961,251 | Common | SOLE |
| 01444V103 | ANNA | ALEANNA INC | $78,993 | 0.00% | 27,717 | Common | SOLE |
| 01444V111 | ANNAW | ALEANNA INC | $69,335 | 0.00% | 490,000 | Common | SOLE |
| G6202B119 | MNYWW | MoneyHero Ltd | $38,306 | 0.00% | 895,000 | Common | SOLE |
| 320703408 | CLDI | CALIDI BIOTHERAPEUTICS INC | $1,219 | 0.00% | 1,042 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.